Noninvasix Presents Novel Fetal Welfare Monitoring System at Discover University of Texas System Future Finders, a SXSW Interactive Event
Galveston, TX, March 10, 2015 --(PR.com)-- Noninvasix, Inc., a medical device company using patented optoacoustic technology for the safe, accurate and noninvasive monitoring of fetal welfare during labor and delivery, will be among the innovative start-up companies spun out from the campuses of the University of Texas System on display at Discover UT Future Finders, a SXSW Interactive Event. The free event will take place Saturday, March 14 from 3:30 – 6:30 p.m. at the Ashbel Smith Hall located at 201 West 7th Street in Austin, Texas.
“What better place than at SXSW to show off the best innovations coming out of the UT System. We look forward to showcasing our first-in-class fetal monitoring system and representing UTMB,” said Noninvasix CEO Graham Randall, Ph.D.
Unlike traditional fetal welfare monitoring systems, which use changes in basal heart rate to indirectly assess fetal asphyxia, Noninvasix’s novel solution utilizes optoacoustic monitoring of cerebral venous oxygenation in the superior sagittal sinus to directly measure the amount of oxygen available to the baby’s brain.
Using a fetal probe, short laser pulses into the superior sagittal sinus, a large central cerebral vein located immediately beneath the top of the skull, generate acoustic waves, which are sent to an electronic monitoring system for signal amplification, acquisition, and recording. Because the generated ultrasound signal returns in a straight line from the superior sagittal sinus, the actual saturation of hemoglobin in the superior sagittal sinus can be accurately determined.
In addition to an exhibit of leading innovations, the Future Finders event will feature a two-part discussion/conversation and reception led by moderator Cecilia Conrad, Ph.D., vice president of the MacArthur Fellows Program.
In Part I, Conrad will lead a conversation with some of the brightest minds within the University of Texas System including UT Medical Branch Galveston professor Thomas Geisbert, Ph.D., who in 2014 was named one of Time Magazine’s “People the Year” for his research on fighting the Ebola virus, and Laurence Cooper, M.D., Ph.D. who leads the Pediatric Cell Therapy Program at MD Anderson. Cooper is providing new hope against aggressive childhood cancers by developing and manufacturing targeted therapies.
In Part II, Conrad will lead a conversation about innovation and the future of medicine with Robert Metcalfe, Ph.D., professor of Innovation and Murchison Fellow of Free Enterprise at the University of Texas at Austin and Mini Kahlon, Ph.D., vice dean for Partnership & Strategy at the University of Texas Dell Medical School.
The event is expected to draw industry leaders, investors and entrepreneurs. For more information, visit www.sxsw.com.
About Noninvasix, Inc.
Using patented optoacoustic technology, Galveston, Texas-based Noninvasix, Inc. has developed a solution for the safe, accurate and noninvasive monitoring of fetal welfare during labor and delivery. Noninvasix is undertaking to significantly improve outcomes for mother and baby during labor, while reducing malpractice lawsuits and premiums, is backed by 15 years of optoacoustic research and more than $6.5 million in research grants.
“What better place than at SXSW to show off the best innovations coming out of the UT System. We look forward to showcasing our first-in-class fetal monitoring system and representing UTMB,” said Noninvasix CEO Graham Randall, Ph.D.
Unlike traditional fetal welfare monitoring systems, which use changes in basal heart rate to indirectly assess fetal asphyxia, Noninvasix’s novel solution utilizes optoacoustic monitoring of cerebral venous oxygenation in the superior sagittal sinus to directly measure the amount of oxygen available to the baby’s brain.
Using a fetal probe, short laser pulses into the superior sagittal sinus, a large central cerebral vein located immediately beneath the top of the skull, generate acoustic waves, which are sent to an electronic monitoring system for signal amplification, acquisition, and recording. Because the generated ultrasound signal returns in a straight line from the superior sagittal sinus, the actual saturation of hemoglobin in the superior sagittal sinus can be accurately determined.
In addition to an exhibit of leading innovations, the Future Finders event will feature a two-part discussion/conversation and reception led by moderator Cecilia Conrad, Ph.D., vice president of the MacArthur Fellows Program.
In Part I, Conrad will lead a conversation with some of the brightest minds within the University of Texas System including UT Medical Branch Galveston professor Thomas Geisbert, Ph.D., who in 2014 was named one of Time Magazine’s “People the Year” for his research on fighting the Ebola virus, and Laurence Cooper, M.D., Ph.D. who leads the Pediatric Cell Therapy Program at MD Anderson. Cooper is providing new hope against aggressive childhood cancers by developing and manufacturing targeted therapies.
In Part II, Conrad will lead a conversation about innovation and the future of medicine with Robert Metcalfe, Ph.D., professor of Innovation and Murchison Fellow of Free Enterprise at the University of Texas at Austin and Mini Kahlon, Ph.D., vice dean for Partnership & Strategy at the University of Texas Dell Medical School.
The event is expected to draw industry leaders, investors and entrepreneurs. For more information, visit www.sxsw.com.
About Noninvasix, Inc.
Using patented optoacoustic technology, Galveston, Texas-based Noninvasix, Inc. has developed a solution for the safe, accurate and noninvasive monitoring of fetal welfare during labor and delivery. Noninvasix is undertaking to significantly improve outcomes for mother and baby during labor, while reducing malpractice lawsuits and premiums, is backed by 15 years of optoacoustic research and more than $6.5 million in research grants.
Contact
Noninvasix
Anna Drake
713-510-0500
Anna Drake
713-510-0500
Contact
Categories